**Curriculum Vitae - Univ. Prof. Dr. rer. nat. Mathias Heikenwälder**

## Personal Data

| | |
|---|---|
| Title | Univ. Prof. Dr. rer. nat. |
| First name | Mathias |
| Name | Heikenwälder |
| Current positions | Full Professor (W3, permanent) |
| Current institution/site, country | The M3 Research Center, University Hospital Tübingen, Tübingen, Germany |
| Identifiers/ORCID | 0000-0002-3135-2274 |

## Qualifications and Career

| Stages | Periods and Details | |
|---|---|---|
| Degree program | **1994 - 1999** | Studies of Microbiology and Genetics, Max-Perutz Laboratories and Institute of Molecular Pathology, University of Vienna, Austria |
| Doctorate | **2000 - 2004** | Ph.D. Thesis, Institute of Neuropathology, University Hospital Zurich, Switzerland. Grade: *summa cum laude* |
| Stages of academic/ professional career | **Since 10/2022** | Scientific/Executive director of The M3 Research Center, University of Tübingen |
| | **Since 10/2022** | Full Professor W3, University of Tübingen |
| | **Since 2015** | DKFZ, Head of the division “Chronic inflammation and cancer”, Heidelberg, Germany |
| | **2015 - 2022** | Full Professor W3, University of Heidelberg |
| | **2010 - 2015** | W2-Professor, TU München |
| | **2010 - 2015** | Helmholtz Young Group Investigator, Helmholtz-Zentrum München |
| | **2010 - 2015** | Peter-Hans Hofschneider Professor for Chronic inflammation and Cancer, Stiftung Experimentelle Medizin |
| | **2009** | Habilitation and Venia Legendi in Experimental Pathology, Medical Faculty, University Hospital Zürich, Switzerland (mentor Prof. Dr. Holger Moch; Prof. François Verrey) |
| | **2007-2010** | Prof. Dr. Max-Cloëtta fellow (Ass. Prof.) and independent group leader, Department of Pathology and start as a principal investigator, University of Zurich, Switzerland |
| | **2006** | Staff scientist and lecturer, Department of Pathology, Institute of Neuropathology, University of Zurich, Switzerland |
| | **2004** | Postdoctoral fellow, Institute of Neuropathology, Pathology Department, University Hospital Zurich, Switzerland |

## Activities in the Research System

*Committees and (inter)national boards (selection)*

Since 2023 Executive Board, Comprehensive Cancer Center Tübingen.
Since 2022 External Scientific Advisory Board, NIHR Birmingham BRC, UK.
Since 2020 Scientific Adisory Board, PSC/PBC program, Mayo Clinic, Rochester, USA.
Since 2024 Scientific Advisory Board, Deutsche Krebshilfe, Bonn.
Since 2018 Scientifc Advisory Board, Peter-Hans Hofschneider Stiftung, Zurich, Switzerland.

*Coordination of* joint *funding programs and organizer of scientific meetings*

2025 Organizer of the Digestive Disease Mechanism (DDM) Summit at UEG, Berlin.
2023 Organizer of the EASL Liver Cancer Summit Estoril, Portugal.
2022 Organizer of the Scientific Summit, EASL conference, London, UK.
2017 - 2022 Scientific co-cordinator of the Helmholtz Alliance "Inflammation and Immunity", German Cancer Research Center, Heidelberg.

*Scientific management education*

2021 - 2022 Helmholtz Circle Advanced Management Course, Helmholtz Academy, Berlin.
2011 - 2013 Certified "*Science Manager*", Malik Management School, St. Gallen, Switzerland and Helmholtz academy for leadership.

*Ad hoc referee for scientific journals (selection)*

Nature, Nature Immunology, Nature Metabolism, Nature Medicine, Nature Cell Biology, Nature Methods, Nature Communications, Cell Metabolism, Cell, Science, Lancet Oncology, Cancer Research, Cancer Discovery.

*Ad hoc referee for funding agencies and organizations (selection)*

Cancer Research UK (GB), Swiss National foudnation (SNF), Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft.

**Supervision of Researchers in Early Career Phases**

- *Supervision of Postdoctoral Researchers and Clinician Scientists*
  12 postdoctoral researchers (7 male, 6 female), 5 Clinician scientists (3 male, 2 female)
- *Supervision of PhD students*
  21 PhD students completed (10 male, 11 female)
- *Supervision of Master students and Bachelor Students*
  8 Master students (5 male, 3 female), 4 Bachelor students (3 male, 1 female)

**Scientific Results**
**Category A**

** senior author, §co-shared senior authors

1. ** Li X, Lebeaupin C, Kadianaki A, […], Kaufmann R**§.**, **Heikenwalder M§.** „Chronically activated ATF6α is a hepatic tumor-driver metabolically restricting immunosurveillance". **Nature**, 2026 January, in press.
2. ** Kommoss KS, Krishnarajah S, Bieler T, Friebel E, Rindlisbacher L, Ramadori P, Häne P, Kam S, Müller F, Prokosch S, Rothermel U, Wu Y, Barletta F, Czemmel S, Nahnsen S, Helm D, Schneider M, Schäkel K, Enk A, Becher B, **Heikenwälder M**. „Single cell mapping identifies a distinct platelet-phenotype in psoriatic type III inflammation". **Nature Communications**, **2025;**16(1):10881. doi: 10.1038/s41467-025-65894-7.
3. **** Gallage S, Ali A, Barragan Avila JE, Seymen N, Ramadori P, Joerke V, Zizmare L, Aicher D, Gopalsamy IK, Fong W, Kosla J, Focaccia E, Li X, Yousuf S, Sijmonsma T, Rahbari M,

Kommoss KS, Billeter A, Prokosch S, Rothermel U, Mueller F, Hetzer J, Heide D, Schinkel B, Machauer T, Pichler B, Malek NP, Longerich T, Roth S, Rose AJ, Schwenck J, Trautwein C, Karimi MM, **Heikenwalder M**. "A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1".
**Cell Metabolism, 2024;** 36(6):1371-1393.e7. doi: 10.1016/j.cmet.2024.04.015

4. ** Pfister D, Núñez NG, Pinyol R, […], Llovet JM[§], **Heikenwalder M[§].** „NASH limits anti-tumour surveillance in immunotherapy-treated HCC".
**Nature, 2021**; 592(7854): 450-456. doi: 10.1038/s41586-021-03362-0.

5. ** Conlon TM, John-Schuster G, Heide D, […], Königshoff M, **Heikenwalder M***, Yildirim AÖ*. „Inhibition of LTβR signalling activates WNT-induced regeneration in lung".
**Nature, 2020**; 588(7836): 151-156. doi: 10.1038/s41586-020-2882-8.

6. O'Connor T, Zhou X, Kosla J, […], Keller U, **Heikenwalder M**. "Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention".
**Cancer Cell, 2019;** 36(3): 250-267.e9. doi: 10.1016/j.ccell.2019.08.001.

7. ** Malehmir M, Pfister D, Gallage S, […], Unger K, Zender L, Nieswandt B, Gawaz M, Weber A[§], **Heikenwalder M[§]**. "Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer".
**Nature Medicine, 2019**; 25(4): 641-655. doi: 10.1038/s41591-019-0379-5.

8. ** Lorentzen A, Becker PF, […], Borsig L, **Heikenwalder M**. "Single cell polarity in liquid phase facilitates tumour metastasis".
**Nature Communications, 2018**; 9(1): 887. doi: 10.1038/s41467-018-03139-6.

9. ** Yuan D, Huang S, Berger E, Pikarsky E, Hüser N, Davis RJ, Tschaharganeh DF, Rad R, Weber A, Zender L, Haller D[§], **Heikenwalder M[§]**. "Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS".
**Cancer Cell, 2017**; 31(6): 771-789.e6. doi: 10.1016/j.ccell.2017.05.006.

10. ** Wolf MJ, Adili A, Piotrowitz K, […], Knolle P*, Weber A*, **Heikenwalder M[§].** "Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes".
**Cancer Cell,2014;** 26(4): 549-564. doi: 10.1016/j.ccell.2014.09.003.

**Category B**

Heikenwälder M, Zender L, EP000003475425A1 Treatment of non-alcoholic steato-hepatitis (NASH)

**Academic Distinctions, prizes**

| | |
|---|---|
| 2026-2031 | ERC Syngery grant "Hepatomodulator" |
| 2018-2025 | Most highly cited researcher ("Cross Topic" Web of Science) |
| 2024-2028 | EU Horizon Grant "THRIVE" (Co-Coordinator) |
| 2022 | German Cancer Award |
| 2020-2021 | ERC Proof of concept (POC) grant |
| 2019 | Elected Member of the Leopoldina, Section XIV |
| 2018 | Swiss Prize for Liver Gastroenterology |
| 2015-2020 | ERC Consolidator Grant |
| 2012 | Walther and Christine Richtzenhain Award, DKFZ, Heidelberg; |

| | |
|---|---|
| 2010-2015 | ERC Starting Grant |
| 2009 | Götz Prize, University of Zurich, Switzerland. |
| 2006 | Empiris Award for brain research, Empiris foundation for brain research, Zurich Switzerland |
| 2004 | Research grant from the University of Zurich, Switzerland, to initiate an independent research group |
| 2004 | Creutzfeldt Science Prize, Creutzfeldt-Stiftung, Kiel |
| 1999-2000 | Erasmus scholarship from the European Community and merit-based scholarship from the University of Vienna, Austria |